Gujarat Terce Laboratories Ltd
Incorporated in 1985. Gujarat Terce Laboratories Ltd is engaged in development, manufacturing, marketing and distribution of medicines, healthcare products and branded generics
- Market Cap ₹ 50.5 Cr.
- Current Price ₹ 68.0
- High / Low ₹ 70.9 / 16.6
- Stock P/E
- Book Value ₹ 13.0
- Dividend Yield 0.00 %
- ROCE %
- ROE %
- Face Value ₹ 10.0
Pros
Cons
- Stock is trading at 5.25 times its book value
- Company has low interest coverage ratio.
- Promoter holding is low: 37.0%
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Formulations
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2019 | Mar 2020 | Mar 2021 | |
|---|---|---|---|
| 31.03 | 37.54 | 25.18 | |
| 30.54 | 36.86 | 27.95 | |
| Operating Profit | 0.49 | 0.68 | -2.77 |
| OPM % | 1.58% | 1.81% | -11.00% |
| 0.32 | 0.29 | 0.80 | |
| Interest | 0.25 | 0.29 | 0.39 |
| Depreciation | 0.21 | 0.24 | 0.18 |
| Profit before tax | 0.35 | 0.44 | -2.54 |
| Tax % | -25.71% | 36.36% | 0.39% |
| 0.43 | 0.28 | -2.52 | |
| EPS in Rs | 0.58 | 0.38 | -3.40 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | -33% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | -1000% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 20% |
| 5 Years: | 51% |
| 3 Years: | 89% |
| 1 Year: | 236% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| Last Year: | % |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2019 | Mar 2020 | Sep 2021 | |
|---|---|---|---|
| Equity Capital | 7.42 | 7.42 | 7.42 |
| Reserves | 3.41 | 3.69 | 2.19 |
| 0.65 | 2.38 | 4.11 | |
| 7.86 | 8.85 | 11.23 | |
| Total Liabilities | 19.34 | 22.34 | 24.95 |
| 2.06 | 2.30 | 3.53 | |
| CWIP | 0.00 | 0.00 | 0.00 |
| Investments | 0.29 | 0.27 | 0.28 |
| 16.99 | 19.77 | 21.14 | |
| Total Assets | 19.34 | 22.34 | 24.95 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2019 | Mar 2020 | Mar 2021 | |
|---|---|---|---|
| Net Cash Flow |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2019 | Mar 2020 | Mar 2021 | |
|---|---|---|---|
| Debtor Days | 53.29 | 68.16 | |
| Inventory Days | 119.66 | 90.00 | |
| Days Payable | 88.95 | 83.71 | |
| Cash Conversion Cycle | 83.99 | 74.46 | |
| Working Capital Days | 33.99 | 48.32 | |
| ROCE % |
Documents
Announcements
- Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate 1d
- Shareholder Meeting / Postal Ballot-Scrutinizer"s Report 25 Apr
- Shareholder Meeting / Postal Ballot-Outcome of EGM 25 Apr
- Revised Submission Of Certificate Under Regulation 40(9) Of SEBI (LODR) Regulations, 2015 For The Year Ended On March 31, 2024 19 Apr
- Submission Of Certificate Under Requlation 40(9) Of SEBI (LODR) Regulations, 2015 For The Year Ended On March 31, 2024 19 Apr
Annual reports
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
-
Financial Year 2010
from bse
-
Financial Year 2009
from bse
Product Profile:[1]
Company has an extensive basket of 50 Brands (125 products) with a portfolio contributing to 10 therapeutic areas, covering multiple dosage forms like Tablets, Capsules, Oral Liquids, Ointments and Injectables.